Thomas P Ahern1, Susan E Hankinson, Walter C Willett, Michael N Pollak, A Heather Eliassen, Rulla M Tamimi. 1. Authors' Affiliations: Channing Division of Network Medicine, Brigham and Women's Hospital & Harvard Medical School; Department of Epidemiology; Department of Nutrition, Harvard School of Public Health, Boston; Division of Biostatistics and Epidemiology, University of Massachusetts School of Public Health and Health Sciences, Amherst, Massachusetts; and Department of Medicine, McGill University, Montréal, Quebec, Canada.
Abstract
BACKGROUND: Insulin may promote breast cancer directly by stimulating the insulin receptor or indirectly by increasing the plasma concentration of active sex hormones. The association between insulin and breast density, a strong breast cancer risk factor, has not been thoroughly studied. We measured associations between c-peptide (a molar marker of insulin secretion), breast cancer risk, and breast density measurements in case-control studies nested within the Nurses' Health Study and Nurses' Health Study II cohorts. METHODS: Breast cancer associations were estimated with multivariate logistic regression models and then pooled across cohorts (total n = 1,084 cases and 1,785 controls). Mammographic density associations (percent dense area, dense area, and nondense area) were estimated as the difference in least-square means of the density parameters between quartiles of c-peptide concentration in all breast cancer controls with available screening mammography films (n = 1,469). RESULTS: After adjustment for adiposity, c-peptide was not associated with any measure of breast density. However, c-peptide was associated with an approximately 50% increased risk of invasive breast cancer [top vs. bottom quartile, adjusted OR = 1.5, 95% confidence interval (CI), 1.1-2.0] that was robust to adjustment for plasma-free estradiol and sex hormone-binding globulin. The association was stronger for ER-negative disease (adjusted OR = 2.0; 95% CI, 1.2-3.6). CONCLUSIONS: Our data suggest a positive association between hyperinsulinemia and breast cancer risk that occurs through nonestrogenic mechanisms, and that is not mediated by breast density. IMPACT: Primary prevention of breast cancer in women with hyperinsulinemia may be possible by targeting insulin signaling pathways.
BACKGROUND:Insulin may promote breast cancer directly by stimulating the insulin receptor or indirectly by increasing the plasma concentration of active sex hormones. The association between insulin and breast density, a strong breast cancer risk factor, has not been thoroughly studied. We measured associations between c-peptide (a molar marker of insulin secretion), breast cancer risk, and breast density measurements in case-control studies nested within the Nurses' Health Study and Nurses' Health Study II cohorts. METHODS:Breast cancer associations were estimated with multivariate logistic regression models and then pooled across cohorts (total n = 1,084 cases and 1,785 controls). Mammographic density associations (percent dense area, dense area, and nondense area) were estimated as the difference in least-square means of the density parameters between quartiles of c-peptide concentration in all breast cancer controls with available screening mammography films (n = 1,469). RESULTS: After adjustment for adiposity, c-peptide was not associated with any measure of breast density. However, c-peptide was associated with an approximately 50% increased risk of invasive breast cancer [top vs. bottom quartile, adjusted OR = 1.5, 95% confidence interval (CI), 1.1-2.0] that was robust to adjustment for plasma-free estradiol and sex hormone-binding globulin. The association was stronger for ER-negative disease (adjusted OR = 2.0; 95% CI, 1.2-3.6). CONCLUSIONS: Our data suggest a positive association between hyperinsulinemia and breast cancer risk that occurs through nonestrogenic mechanisms, and that is not mediated by breast density. IMPACT: Primary prevention of breast cancer in women with hyperinsulinemia may be possible by targeting insulin signaling pathways.
Authors: Roni T Falk; Louise A Brinton; M Patricia Madigan; Nancy Potischman; Susan R Sturgeon; Kathleen E Malone; Janet R Daling Journal: Breast Cancer Res Treat Date: 2006-02-24 Impact factor: 4.872
Authors: Geoffrey C Kabat; Mimi Kim; Bette J Caan; Rowan T Chlebowski; Marc J Gunter; Gloria Y F Ho; Beatriz L Rodriguez; James M Shikany; Howard D Strickler; Mara Z Vitolins; Thomas E Rohan Journal: Int J Cancer Date: 2009-12-01 Impact factor: 7.396
Authors: Mariëtte Lokate; Petra H M Peeters; Linda M Peelen; Gerco Haars; Wouter B Veldhuis; Carla H van Gils Journal: Breast Cancer Res Date: 2011-10-26 Impact factor: 6.466
Authors: Gadi Shlomai; Zara Zelenko; Irini Markella Antoniou; Marilyn Stasinopoulos; Aviva Tobin-Hess; Michael P Vitek; Derek LeRoith; Emily Jane Gallagher Journal: Endocr Relat Cancer Date: 2017-10 Impact factor: 5.678
Authors: Fred K Tabung; Teresa T Fung; Jorge E Chavarro; Stephanie A Smith-Warner; Walter C Willett; Edward L Giovannucci Journal: Int J Cancer Date: 2016-11-14 Impact factor: 7.396
Authors: Maureen Sanderson; Heather O'Hara; Nia Foderingham; William D Dupont; Xiao-Ou Shu; Neeraja Peterson; Alecia M Fair; Anthony C Disher Journal: Cancer Causes Control Date: 2014-11-25 Impact factor: 2.506
Authors: Maryam S Farvid; A Heather Eliassen; Eunyoung Cho; Wendy Y Chen; Walter C Willett Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-03-24 Impact factor: 4.254
Authors: Jun Wang; Xuehong Zhang; Andrew H Beck; Laura C Collins; Wendy Y Chen; Rulla M Tamimi; Aditi Hazra; Myles Brown; Bernard Rosner; Susan E Hankinson Journal: Horm Cancer Date: 2015-09-18 Impact factor: 3.869
Authors: Jae H Kang; Cheng Peng; Jinnie J Rhee; Maryam S Farvid; Walter C Willett; Frank B Hu; Bernard A Rosner; Rulla Tamimi; A Heather Eliassen Journal: Am J Clin Nutr Date: 2020-12-10 Impact factor: 7.045